Introduction

The definition of an adrenal incidentaloma (AI) encompasses any focal adrenal lesion, independent of size, discovered by any imaging method including ultrasonography (US), endoscopic ultrasonography (EUS), computed tomography (CT), or magnetic resonance imaging (MRI), in the absence of adrenal disease.
Due to the fact that the adrenal glands are the fourth most frequent site of metastasis, independent of the location of the primary tumor (prevalence of metastases: 27%) [1–3], the definition excludes adrenal lesions that are detected in patients with a suspected or established diagnosis of malignancy [4–6]. However, in patients with a known malignancy, more than 50% (9%–75%) of solid adrenal masses turn out not to be metastases [7]. Whereas the published literature is full of CT reports, comparatively little has been published for US, which is still the imaging method with the most detailed resolution. Conventional US and EUS both allow visualization of the normal adrenal gland and its vascularity (Figs. 1, 2). It is possible to detect focal lesions down to 3–5 mm, in particular with transabdominal US for the right gland and with EUS for the left gland (Figs. 3, 4) [7–9]. Nevertheless some definitions include only adrenal mass lesions ≥10 mm [10,11], as the normal thickness of the body of the adrenal glands varies from 6 to 8 mm (±2 mm) [12]. The most frequent pathology underlying an AI is a nonfunctional adenoma [7,11].

After detection of an AI, there are a few important questions to be answered to determine the need for treatment: (1) What is the prevalence?; (2) Is the AI malignant?; (3) Does the AI have endocrine activity?

**Adrenal Incidentaloma**

**Prevalence**

The prevalence of AIs of any size with imaging is reported to be about 5%, ranging from 1% to 12% (with higher rates in older age groups) and the frequency of AIs has approached 8.7% in...
Adrenal incidentaloma

In patients with a high body mass index, diabetes mellitus, and arterial hypertension, the prevalence is even higher [15,16]. Bilateral AIs are found in about 10%-15% of cases [17-19]. In unselected healthy subjects and in patients with inflammatory bowel disease, a prevalence of 5% was reported using abdominal US [8,20-22]. By far the largest data sets have been collected using CT. With state-of-the art contemporary CT examinations, AI was found in 4.4%-5% of individuals [23–25]. In older studies, the reported prevalence was much lower for both methods, with AIs found in 259 of 61,054 individuals (0.4%) using CT scans performed from 1985 to 1990 [26], and rates of 0.1% [27] or less [28] using abdominal US. Therefore, AI was described to be "a 'disease' of modern imaging technology" [29]. The main role of imaging is therefore to limit the invasive management of AI, and particularly the number of surgical adrenalectomies and biopsies.

Is the AI Malignant?

As shown for focal liver lesions [30,31], but also in AI, primary or secondary malignancies in asymptomatic subjects are an uncommon finding [11,15,32–34]. The most recent systematic review found a mean prevalence of adrenocortical carcinoma of 1.9% (median, 1.4%) and a mean prevalence of metastases of 0.7% (median, 0.2%). It concluded that due to various biases and misinterpretations of reports, previous reviews have overestimated the risk that an AI is malignant. According to newer data, the real cumulative risk of malignancy in AI may be below 3% [11].

Size

Importantly, the size and some imaging features are helpful in determining whether an AI is benign or malignant [33–35]. A diameter >40 mm is a crucial cut-off since >90% of adrenocortical carcinomas are >40 mm at the time of diagnosis [17,26,34,36].

On the contrary, the smaller the size at the time of diagnosis, the better the prognosis [37]. A systematic review showed that only 2% of all adrenal masses ≤4 cm turned out to be adrenal carcinoma, whereas the prevalence of adrenocortical carcinoma in adrenal masses measuring 4–6 cm was 6%, and in tumors >6 cm it significantly increased to 25% [38]. According to a more recent meta-analysis, the cut-off value of 40 mm for malignancy had an area under the curve of 0.92 with high sensitivity (91%), but limited specificity (71%). The pooled positive (3.1) and negative likelihood ratio (0.13) of this 40-mm cut-off value are neither confirmative nor exclusive for malignancy, so that further parameters are needed for a definitive diagnosis [39].

Imaging Features

In addition to size, some imaging features should be considered. Most important are the smooth border of a lesion and the amount of fat (attenuation values below 10 Hounsfield units [HU] in unenhanced CT) in benign lesions [40–42]. In AIs >40 mm, criteria correlating with the diagnosis of adenoma versus adrenocortical carcinoma are a round shape, the presence of fat, and precontrast attenuation values <10 HU. Moreover an overall impression of a benign lesion ("benign imaging phenotype") was described to be significantly correlated with the diagnosis of adenoma [43]. In a blinded retrospective study, interobserver agreement was reported to be excellent for precontrast attenuation, substantial for shape, moderate for the presence of fat, and fair for overall impression of benignity. Among the features of malignancy, the presence of calcifications had substantial interobserver agreement, whereas agreement for heterogeneity was only fair and agreement for the presence of necrosis was marginal [43].

MRI is less often used, but the so-called chemical-shift imaging techniques give equivalent results for the estimated amount of fat. The descriptive features for benign AI are an oval or round shape, sharp margins and smooth contour, and homogeneous echo pattern (US) or density (CT). In conclusion, an approach combining size (<40 mm) and HU values (<10 HU) excludes malignancy in almost all cases [39,44]. However, approximately 30% of benign adrenal adenomas are lipid-poor, with attenuation values of ≥10 HU [45].

Contrast-Enhanced Techniques

Results of studies using contrast enhancement for all imaging methods, including contrast-enhanced US, are less convincing...
Specific quadriphasic contrast-enhanced adrenal CT protocols with higher radiation exposure allow calculation of absolute and relative wash-out [10]. Earlier wash-out in fat-containing adenoma and delayed wash-out in metastasis is observed [39,46,47,52–54]. A combination of unenhanced CT and wash-out CT calculation with delayed phase acquisition at 15 minutes for adrenal lesions with attenuation values ≥10 HU was shown to provide high sensitivity and specificity for differentiating adenomas from non-adenomas (98% and 92%, respectively) [52]. Delayed contrast-enhanced CT is more effective for diagnosis than chemical-shift MRI.

With contrast-enhanced US, the combination of early arterial hyperenhancement and rapid wash-out was described to be highly sensitive for the diagnosis of malignancy, but specificity was only moderate [49,50]. Another study did not find significant differences between malignant and benign adrenal masses with regard to the pattern of contrast enhancement [48]. However, contrast-enhanced US may be very helpful for detecting hypervascularity and intratumoral hemorrhage or necrosis, such as in pheochromocytoma (Fig. 5).

Combined Imaging Criteria
With all imaging techniques, the typical imaging features of adrenocortical carcinoma and metastases are a size >40–60 mm, irregular shape, inhomogeneous echo pattern, calcifications and non-enhancing spontaneous hemorrhage necrosis. Metastases tend to be bilateral [39,55–57].

Combining various parameters from unenhanced and contrast-enhanced CT and patient-related clinical data significantly improves the diagnostic performance for differentiating between benign and malignant adrenal lesions beyond that of single parameters [58–60].

Other differential diagnoses (e.g., adrenal cysts and myelolipoma) show typical imaging features and do not need further work-up [7,9,61].

Image-Guided Biopsy
In contrast to patients with suspected or proven malignant disease with solid adrenal tumors, in AI the role of image-guided biopsy is limited. Recent guidelines do not recommend image-guided sampling for routine work-up of AIs [4,6,62]. A meta-analysis found percutaneous image-guided biopsy to have a sensitivity and specificity of 87% and 100%, respectively, for the diagnosis of malignancy. Definitive differentiation of adrenocortical carcinoma from adenoma is not possible in all cases. The pooled complication rate was 2.5% [63]. For EUS-guided sampling, data are more limited. The diagnostic yield ranges from 76% to 100%, and the risk of complications is very low [64–66].

In case of equivocal results of imaging, image-guided
sampling aiming at histological specimens may be preferred over adrenalectomy [67]. Pheochromocytoma should be ruled out prior to biopsy [68–70].

**Does the AI Have Endocrine Activity?**
Most AIs are nonfunctional (about 90%) [11,34]. A meta-analysis summarized the following data for the mean prevalence of functional AIs: nonfunctional, 89.7%; Cushing’s syndrome, 6.4%; pheochromocytoma, 3.1%; and primary aldosteronism, 0.6% [11]. In a large prospective Swedish AI cohort (n=226) the prevalence of endocrine activity was only 3.1% [71].

Pheochromocytoma and (subclinical) Cushing’s syndrome should be excluded in all patients with AI. In patients with arterial hypertension with or without hypokalemia, Conn syndrome should be excluded.

**Pheochromocytoma**
Pheochromocytomas (3% of AIs) are typically >40 mm at time that significant hormone production is diagnosed [72,73], highly vascularized, sometimes ectopic (about 10%), and multiple (about 10%) [11,74,75]. The final diagnosis is achieved by measuring plasma metanephrines.

All patients with proven pheochromocytoma should undergo surgery. Multiple endocrine neoplasia should be considered [76,77].

**Cushing’s Syndrome**
Subclinical Cushing’s syndrome (SCS) is defined by autonomous cortisol secretion (detected by ≥2 abnormalities in a basal or dynamic test of the hypothalamic-pituitary-adrenal axis in patients who do not have the typical signs and symptoms of hypercortisolism). SCS is excluded by performing the 1 mg overnight dexamethasone suppression test (DST) [4]. Cortisol might be secreted either dependently or independently of corticotropin (ACTH). Unilateral adenoma with or without somatic mutations in the cAMP-dependent protein kinase A or bilateral macronodular adrenal hyperplasia (BMAH) are found [78,79]. Recurrent vertebral fractures [80] and less specifically, arterial hypertension, impaired glucose tolerance, or type 2 diabetes mellitus are typical [81–83].

An abnormal DST indicates ACTH-independent cortisol production (positive if cortisol concentration >5 μg/dL [>138 nmol/L]). As a consequence, 24-hour urinary free cortisol and serum ACTH concentrations should be tested and evaluation of dehydroepiandrosterone sulfate metabolism should be performed, as well as a high-dose (8 mg) overnight DST. Clinically significant glucocorticoid secretory autonomy is confirmed by a test of early-morning DST serum cortisol levels. Autonomous glucocorticoid function may also develop over time; therefore, follow-up testing should be considered [33,36,84,85]. However, the efficiency and cost-effectiveness of annual repeated testing is not known [11,15].

The indications for unilateral (or very rarely bilateral) adrenalectomy [86] are beyond the scope of this review [87–89]. Briefly, adrenalectomy is recommended for younger patients with proven SCS (excess of glucocorticoid secretion) and those at risk (e.g., with known osteoporosis, arterial hypertension, diabetes mellitus, and obesity). The benefits of adrenalectomy in patients with adrenal tumors and SCS have been suggested in a recent meta-analysis [90].

**Hyperaldosteronism and Conn Syndrome**
Aldosteronomas (<1% of AIs) are typically <20 mm at the time of diagnosis, poorly vascularized, and most often circumscribed. Diffuse mild hyperplasia <10 mm can be encountered. The diagnosis is achieved by measuring the plasma aldosterone concentration to plasma renin activity ratio [33,91].

In younger patients with unilateral aldosterone-producing adenoma, surgery should be offered to cure the aldosterone excess, whereas aldosterone-antagonistic drugs are the treatment of choice in cases of bilateral hyperplasia with hyperaldosteronism and generally in older patients with comorbidities [92].

**Nonfunctional AI**
Nonfunctional AI (NFAI) should be considered for surgery if >40 mm due to the risk of malignancy, in particular adrenal cortical carcinoma (ACC) [37,91]. The detection of NFAI is predictive of the presence of diabetes mellitus and metabolic syndrome [93,94]. Smaller NFAs may be scheduled for repeated imaging after 6 to 12 months to exclude significant growth and, therefore, malignancy [15]. Significant growth is considered to be enlargement >10 mm in diameter during the follow-up period. It should be pointed out that most NFAs that grow are not malignant. The decisions about whether to utilize other imaging techniques, the type of imaging for follow-up, and the time interval are mainly guided by the local circumstances and individual decisions. CT-related radiation exposure should be considered [11].

Adrenal myelolipoma (AML) is a slowly growing benign tumor composed of hematopoietic elements and fat elements with eye-catching imaging features [95]. AML is typically hyperechoic using conventional US and EUS (Fig. 6) and shows abundant fat using CT and MRI.

Many other rare focal adrenal lesions may be encountered.

**Bilateral AI**
Patients with bilateral AI should be investigated for Cushing’s disease, congenital adrenal hyperplasia, and BMAH [19,96]. The indication for surgery in bilateral NFAI is more restricted.
Follow-up
Follow-up by repeat imaging and hormonal work-ups is recommended by most recent guidelines for individuals with AI with a benign imaging phenotype and no hormonal activity at initial presentation [5,6,10,38,62,97,98]. Adherence to these recommendations seems to be generally poor in clinical practice [99–101]. Moreover, most follow-up studies have shown negligible risk of an AI that is consistent with a benign and nonfunctional lesion at initial presentation becoming malignant (0%) or hormonally active (below 0.3%) [4,11,71,102]. Based on a systematic review of the available data, a review highlighted the high risk of false-positive results of the recommended examinations and cautioned that the dose of radiation with CT follow-up confers a risk of fatal cancer that is similar to the risk of the AI becoming malignant [11]. Another meta-analysis showed no risk of developing malignancy in 1,298 AIs (pooled from 11 studies) followed for a mean of 44.2 months. Size progression was only marginal (pooled mean increment of 0.03 cm), and the development of endocrine activity was rare (SCS, 1.8%; Cushing’s syndrome, 0.7%; pheochromocytoma, 0.4%) [103]. Therefore, the guidelines of the European Society of Endocrinology (ESE) in 2016 suggested omitting further follow-up imaging in individuals with an adrenal mass <40 mm and with clear benign features on imaging studies [4]. Moreover, the ESE guidelines suggested against repeated hormonal assessments in individuals with AI who have a normal hormonal work-up at the time of initial presentation, unless clinical signs of endocrine activity develop or metabolic comorbidities or arterial hypertension worsens [4]. Imaging follow-up was recommended for patients with indeterminate adrenal masses opting against adrenalectomy. In case of growth of ≥5 mm and enlargement by >20%, surgical resection is recommended [4]. Other societies suggest using CT protocols with reduced radiation exposure [10] or to individualize follow-up recommendations [62,97,98]. The Polish Society of Endocrinology recommended using abdominal US for follow-up in appropriate cases [62].

Adrenalectomy
Adrenalectomy for NFAI <60 mm is most often performed laparoscopically (less pain, shorter hospitalization, less blood loss, and faster recovery compared to open surgery), but the endoscopic posterior approach [104] and conventional open surgery (3) are alternatives. Open surgery is recommended for ACC, but the laparoscopic approach can be considered in tumors <10 cm [105–111].

All procedures are reported to be relatively safe [112].

Clinical Scenarios and Role of Ultrasonography

Detection of AI by Transabdominal Ultrasonography
US has a high sensitivity for the detection of adrenal mass lesions (in particular for the right gland), even in tumors <20 mm [9]. Therefore, incidental detection of adrenal tumors is a frequent clinical scenario. In a patient/individuals without history, suspicion, or proof of malignant disease, an AI with a maximum diameter of ≤40 mm, a homogeneous echo-rich echo pattern (myelolipoma) and smooth borders or a typical cystic (completely anechoic) pattern (“benign US phenotype”) in all likelihood is benign [7]. However, prospective studies comparing the diagnostic accuracy of US to that of unenhanced CT are lacking. Contrast-enhanced US is not helpful for distinguishing malignant and benign lesions.

Therefore, in addition to a hormonal work-up, unenhanced CT should be performed in lesions ≥10 mm. If endocrine activity is lacking and CT findings are highly predictive for a benign lesion, further imaging or regular follow-up is not necessary. In cases of equivocal CT findings or hormonal activity, further management should be based on a multidisciplinary expert board discussion. Further management options in cases of functional AI are described above. In cases of an incidental adrenal mass with equivocal CT criteria or a diameter of >40 mm and <60 mm, an individualized decision should be made, considering close follow-up, surgery, or further imaging (chemical phase-shift MRI) [1]. (E)US- or CT-guided sampling may also be an option in individual cases (e.g., size >40 mm and <60 mm or no definite benign imaging phenotype on imaging, with patient-related factors making surgery less favorable) [3,7]. For smaller lesions, a hormonal work-up should be performed, and follow-up by ultrasound seems reasonable.

Fig. 6. Transabdominal ultrasound of a huge hyperechoic mass of the right adrenal gland. This finding is typical for the rare diagnosis of adrenal angiomyolipoma.
Detection of Al by Cross-sectional Imaging (CT, MRI)
In AIs detected using cross-sectional imaging techniques, the role of US and EUS is limited. Performing US may be useful if, as a result of further work-up, surgery is not the appropriate management strategy for the patient and follow-up is required. If US enables appropriate visualization and measurement of the lesion, due to the absence of radiation exposure, US may be preferable to CT for surveillance [62].

Summary
All patients with an Al >10 mm should be evaluated at initial presentation to exclude malignancy and hormonal hyperfunction according to recent guideline recommendations [4]. In cases of a “benign imaging phenotype” on US, additional unenhanced CT should be performed in all lesions ≥10 mm that are not completely anechoic with smooth borders (typical cysts). AIs measuring <40 mm, with a smooth border and CT attenuation value <10 HU, are most probably benign. After exclusion of hormonal activity, a further diagnostic work-up is not recommended. However, it is recommended to compare with any prior imaging examinations to evaluate any changes in size. AIs measuring >40 mm and/or with hormonal activity should be considered for surgery. Adrenocortical carcinoma is typically characterized by an irregular shape, an inhomogeneous echo pattern, calcifications, non-enhancing spontaneous hemorrhage necrosis, and higher CT attenuation values (>20 HU), as well as delayed wash-out (on contrast-enhanced CT). Pheochromocytoma is typically >30 mm or >40 mm at time of diagnosis, highly vascularized with regressive changes and zones of spontaneous necrosis, and sometimes ectopic and multiple. The final diagnosis is established by measuring plasma metanephrines. Cushing’s disease is excluded by performing the 1 mg overnight DST. The typical imaging features of Conn syndrome are size <20 mm, an oval or round shape, and a sharply delineated and homogeneous echo pattern. The diagnosis should be considered in patients with arterial hypertension and/or otherwise unexplained hypokalemia, using the plasma aldosterone concentration to plasma renin activity ratio. US should be considered in cases with recommended imaging follow-up, if appropriate US visualization of the mass lesion is possible. In patients with a known primary malignancy elsewhere, the probability of an adrenal mass being metastatic is much higher than in healthy subjects. Histological sampling (US/endoscopic US- or CT-guided) may be considered on an individual basis in patients with an AI measuring >40 mm and <60 mm or with no definite benign imaging phenotype on imaging, or in the case of metastasis (incidentally discovered cancer), if patient-related factors strongly rule out surgery. It has high clinical value in all cases with a history or suspicion of malignancy.

ORCID: Christoph F. Dietrich: https://orcid.org/0000-0001-6015-6347; Yi Dong: https://orcid.org/0000-0002-0212-1477; Christian Nolsoe: https://orcid.org/0000-0003-0168-6131; Susan Campbell Westerway: https://orcid.org/0000-0001-5104-073X; Christian Jenssen: https://orcid.org/0000-0002-7008-6650

Author Contributions
Conceptualization: Dietrich CF, Jenssen C. Data acquisition: Dietrich CF, Correas JM, Dong Y, Nolsoe C, Westerway SC, Jenssen C. Data analysis or interpretation: Dietrich CF, Correas JM, Dong Y, Nolsoe C, Westerway SC, Jenssen C. Drafting of the manuscript: Dietrich CF, Correas JM, Jenssen C. Critical revision of the manuscript: Dietrich CF, Correas JM, Dong Y, Nolsoe C, Westerway SC, Jenssen C. Approval of the final version of the manuscript: all authors.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

References

11. Cawood TJ, Hunt PJ, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 2009;161:513-527.


41. Hammahiah AH, Ioachimescu AG, Remer EM, Motta-Ramirez G,
Adrenal incidentaloma


